Retension Pharmaceuticals, Inc. RTSN
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | |||
|---|---|---|---|---|---|
| Net Income | -24.33% | -51.94% | 0.00% | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 57.40% | 575.54% | 0.00% | ||
| Change in Net Operating Assets | 88.39% | 162.05% | 0.00% | ||
| Cash from Operations | -7.21% | 19.43% | 0.00% | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -- | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -100.00% | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | 0.00% | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | 100.00% | -- | -- | ||
| Cash from Financing | -100.00% | -99.94% | 0.00% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -7.30% | -914.46% | 0.00% | ||